Research and development

Our ambitious programmes aim to substantially reduce global epidemic and pandemic risk. CEPI’s priority diseases include Chikungunya, COVID-19, Ebola, Lassa Fever, MERS, Nipah, Rift Valley Fever, and novel viral threats with epidemic or pandemic potential (also known as “Disease X”).

A team of scientists working on vaccine creating in a modern laboratory
female scientist holding a pipette looking at equipment

Enabling science

From biological standards to preclinical models, CEPI supports enabling science activities to accelerate development of safe and effective epidemic or pandemic vaccines. Read on to learn about the enabling science activities that CEPI supports.

Read more
2 female scientists writing on a whiteboard in a modern laboratory

Vaccine technology

Vaccines are our most potent weapon against infectious diseases and are at the heart of global responses to epidemic and pandemic threats. 

Read more
A female scientist from Biofarma holding a vile of vaccine in a lab

Manufacturing and supply chain

CEPI is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats.

Read more
vaccine glass vials in production as part of vaccine manufacturing

Our portfolio

Our interactive portfolio provides information on each of the vaccine candidates that CEPI has invested in.

Read more

Call for Proposals

We invite innovators worldwide to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.

Apply now
University of Queensland scientists in a lab

Latest News

blue banner image with logos and event title on

Global Summit to bolster pandemic preparedness

Simulation exercise at Munich Security Conference

Bringing the 100 Days Mission to global security leaders

historic image of Edward Jenner administering vaccine
The Viral Most Wanted

The Poxviruses

Dr. Bolaji (left) is the Nigeria-based HJFMRI principal investigator for the IAVI C105 Lassa fever vaccine clinical trial in Abuja, Nigeria. Credit: HJFRMI.

Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial